Mitogen-Activated Protein Kinase (MAPK)

Mitogen-Activated Protein Kinase (MAPK) designates a family of serine/threonine protein kinases that transduce extracellular signals from cell surface receptors to nuclear transcription factors through sequential phosphorylation cascades, regulating fundamental cellular processes including proliferation, differentiation, apoptosis, stress responses, and immune function. These evolutionarily conserved signalling pathways consist of three-tiered kinase modules amplifying signals while providing multiple regulatory checkpoints.

The biopharmaceutical industry extensively targets MAPK pathways for therapeutic intervention given their central roles in cancer, inflammation, metabolic disorders, and neurodegenerative diseases, with dysregulated MAPK signalling driving oncogenesis through constitutive proliferation signals and resistance to apoptosis. Major MAPK subfamilies include ERK1/2 activated downstream of growth factor receptors mediating proliferation and survival, p38 MAPK responding to cellular stress and inflammatory cytokines, and JNK regulating stress responses and apoptosis. Cancer therapy development focuses heavily on MAPK pathway inhibitors, with BRAF inhibitors targeting mutant BRAF V600E in melanoma and MEK inhibitors blocking downstream ERK activation. Combination BRAF plus MEK inhibition demonstrates superior efficacy compared to single-agent therapy while delaying resistance development. As understanding deepens regarding pathway complexity including feedback loops and crosstalk, MAPK-targeted therapeutics continue advancing through improved inhibitor designs and biomarker-guided patient selection.